Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Surgical Mitral Valve Repair Versus Medical Treatment for People With Significant Mitral Regurgitation and Non-ischemic Congestive Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Symptomatic chronic heart failure, New York Heart Association (NYHA) class II to IIIb~* Left ventricular ejection fraction of 0.35 due to non-ischemic etiology~* Evidence by transthoracic echocardiography (TTE) of moderate or severe MR without obvious primary mitral valve pathology~* Peak VO2 less than or equal to 22 ml/kg/min, as obtained at study entry~* Optimal heart failure therapy for at least 6 months prior to study entry~Exclusion Criteria:~* Significant coronary artery disease (greater than 75% lesion in any vessel) by coronary angiography or by a history of a prior heart attack~* Heart failure due to active myocarditis, congenital heart disease, or obstructive hypertrophic cardiomyopathy~* Significant ventricular arrhythmias not treated with an implantable defibrillator~* Primary MR due to significant chordal or leaflet abnormalities by TTE~* Other hemodynamically relevant stenotic or regurgitant valvular diseases~* Severe tricuspid regurgitation (TR) (moderate TR is allowed)~* Severe pulmonic regurgitation (PR) (moderate PR is allowed)~* Moderate to severe aortic regurgitation~* Any moderate to severe stenotic lesions using American Heart Association/American College of Cardiology (AHA/ACC) criteria 31~* Dependence on chronic inotropic therapy~* Restrictive cardiomyopathy or constrictive pericarditis~* Severe right ventricular dysfunction~* Baseline creatinine greater than or equal to 3 mg/dL or renal replacement therapy (chronic hemodialysis or peritoneal dialysis)~* Poor transthoracic sonographic windows precluding reasonable assessment of LV endocardial borders from apical imaging on TTE~* Inability to perform the spirometric exercise testing~* Significant chronic lung disease that might interfere with the ability to interpret the spirometric measurements, including home oxygen, forced expiratory volume in 1 second (FEV1) less than 1.0 L/min, or exertional hypoxemia with saturations less than 90%~* Any known neoplastic disease other than skin cancer~* Other terminal illness with a life expectancy less than 1 year~* Plan for percutaneous mitral valve procedure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Participants will receive optimal medical therapy plus surgical mitral valve repair with complete annular ring placement
- 2 (Type: ACTIVE_COMPARATOR): Participants will receive optimal medical therapy alone
- 3 (Type: EXPERIMENTAL): Participants will receive optimal medical therapy plus 18-month delayed surgical mitral valve repair with complete annular ring placement

Based on this trial design, predict the completion outcome and termination type (if applicable).